GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Median PS Value

PVCT (Provectus Biopharmaceuticals) Median PS Value : $0.00 (As of Apr. 02, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Provectus Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0. Provectus Biopharmaceuticals's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2025-04-02), Provectus Biopharmaceuticals's share price is $0.0997. Provectus Biopharmaceuticals's Median PS Value is $0.00. Therefore, Provectus Biopharmaceuticals's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Provectus Biopharmaceuticals's Median PS Value or its related term are showing as below:

PVCT's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Provectus Biopharmaceuticals Median PS Value Historical Data

The historical data trend for Provectus Biopharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Median PS Value Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Provectus Biopharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Provectus Biopharmaceuticals's Median PS Value

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Price-to-Median-PS-Value falls into.


;
;

Provectus Biopharmaceuticals Median PS Value Calculation

Provectus Biopharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Provectus Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provectus Biopharmaceuticals  (OTCPK:PVCT) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Provectus Biopharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0997/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provectus Biopharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Provectus Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
800 S Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The Company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.
Executives
Jeffrey Allen Morris 10 percent owner 1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines officer: Chief Financial Officer 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing director 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass officer: See Remarks 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper officer: Interim CEO, CFO, COO 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter director, officer: Chief Technology Officer PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv director 191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams 10 percent owner 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott director, 10 percent owner, officer: President PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931

Provectus Biopharmaceuticals Headlines

From GuruFocus